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Objectives
To evaluate in a prospective international cohort of juve-
nile systemic lupus erythematosus (JSLE) with active renal
disease (ARD) response to therapy over a 24-month period.
Patients & Methods
134 new onset and 106 flared JSLE patients with ARD, age
< 18 years, were included. JSLE disease activity parameters
and therapeutic approaches were analyzed at baseline, 6,
12 and 24 months, in 4 geographic areas. Response was
assessed according to the PRINTO/ACR JSLE criteria “as
observed” and as “per intention-to-treat (ITT)”.
Results
New patients had higher baseline disease activity com-
p a r e dt of l a r e dp a t i e n t s ,b u ti n i t i a t e dc o r t i c o s t e r o i d sa t
similar doses. Cyclophosphamide was the most common
(41.2%; 99/240) immunosuppressive medication, fol-
lowed by azathioprine (25%; 60/240). Mycophenolate
mofetil and azathioprine were more commonly used in
flared patients. Patients from Latin America received
more pulses and higher doses of steroids when com-
pared to Western Europe. The use of cyclophosphamide
was similar in all 4 regions. In the “as observed” analysis
78% (103/132) of new compared to 57.4% (58/101) of
flared JSLE patients (p=0.0007) reached at least
PRINTO/ACR 70 level of response at 6 months, which
increased to 87.1% in new and 77.2% in flared patients
at month 24 (p=0.12). Corresponding figures for the
ITT analysis were similar and 80% (68/85) of new vs
73.7% (42/57) of flared patients were able to maintain
the initial assigned therapy over 24 months (p=0.38).
Corticosteroids were discontinued in 28.6% (20/143).
Conclusions
Both new and flared patients improved similarly over 24
months. Some differences in therapeutic approaches
exist worldwide.
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